We are live on ! Find out more
VIA

Virtus Investment Advisers Portfolio holdings

AUM $429M
1-Year Est. Return 52.52%
This Fund
S&P 500
This Quarter Est. Return
+23.54%
1 Year Est. Return
+52.52%
3 Year Est. Return
+172.32%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$429M
AUM Growth
+$66.7M
Cap. Flow
+$19.4M
Cap. Flow %
4.52%
Top 10 Hldgs %
7.64%
Holding
517
New
67
Increased
228
Reduced
168
Closed
54

Top Buys

Rank Stock Value
1
DVN icon
Devon Energy
DVN
+$3.47M
2
DDOG icon
Datadog
DDOG
+$2.53M
3
MRVL icon
Marvell Technology
MRVL
+$2.28M
4
WDC icon
Western Digital
WDC
+$2.19M
5
NTAP icon
NetApp
NTAP
+$2.17M

Top Sells

Rank Stock Value
1
DAWN
Day One Biopharmaceuticals
DAWN
+$2.17M
2
LIN icon
Linde
LIN
+$2.08M
3
HSY icon
Hershey
HSY
+$2.06M
4
LYV icon
Live Nation Entertainment
LYV
+$1.97M
5
KO icon
Coca-Cola
KO
+$1.96M

Sector Composition

Rank Sector Weight
1 Healthcare 38.77%
2 Technology 15.15%
3 Financials 13.21%
4 Industrials 12.74%
5 Consumer Discretionary 5.44%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MDGL icon
151
Madrigal Pharmaceuticals
MDGL
$12.1B
$1.3M 0.3%
2,419
+943
+64% +$483K
PTGX icon
152
Protagonist Therapeutics
PTGX
$9.28B
$1.3M 0.3%
10,593
+7,733
+270% +$808K
VRTX icon
153
Vertex Pharmaceuticals
VRTX
$130B
$1.3M 0.3%
2,614
-3,255
-55% -$1.44M
BBIO icon
154
BridgeBio Pharma
BBIO
$13.4B
$1.3M 0.3%
17,408
+6,174
+55% +$432K
ECC
155
Eagle Point Credit Company
ECC
$485M
$1.3M 0.3%
348,534
-119,280
-25% -$475K
ZLAB icon
156
Zai Lab
ZLAB
$2.78B
$1.29M 0.3%
68,124
+20,613
+43% +$407K
GERN icon
157
Geron
GERN
$842M
$1.29M 0.3%
1,011,201
+390,406
+63% +$550K
TGTX icon
158
TG Therapeutics
TGTX
$8.12B
$1.29M 0.3%
23,483
-3,447
-13% -$141K
LDOS icon
159
Leidos
LDOS
$16.2B
$1.29M 0.3%
12,495
+2,355
+23% +$313K
IMCR icon
160
Immunocore
IMCR
$1.64B
$1.27M 0.3%
40,155
+17,215
+75% +$509K
CRSP icon
161
CRISPR Therapeutics
CRSP
$5.01B
$1.27M 0.3%
23,351
+8,457
+57% +$446K
ARWR icon
162
Arrowhead Research
ARWR
$9.98B
$1.27M 0.3%
15,605
+3,560
+30% +$263K
TVTX icon
163
Travere Therapeutics
TVTX
$5.89B
$1.27M 0.3%
22,346
-1,893
-8% -$83.9K
INSM icon
164
Insmed
INSM
$26.2B
$1.27M 0.3%
11,884
+7,601
+177% +$920K
OMER icon
165
Omeros
OMER
$1.24B
$1.27M 0.3%
133,129
+106,264
+396% +$1.26M
CRNX
166
DELISTED
Crinetics Pharmaceuticals
CRNX
$1.26M 0.29%
33,736
+17,015
+102% +$632K
PTCT icon
167
PTC Therapeutics
PTCT
$5.48B
$1.26M 0.29%
15,476
+4,316
+39% +$312K
IONS icon
168
Ionis Pharmaceuticals
IONS
$7.85B
$1.26M 0.29%
15,870
+5,425
+52% +$408K
BIIB icon
169
Biogen
BIIB
$31.9B
$1.26M 0.29%
5,813
+965
+20% +$185K
ONC
170
BeOne Medicines Ltd
ONC
$39.2B
$1.25M 0.29%
4,397
+1,751
+66% +$516K
ARQT icon
171
Arcutis Biotherapeutics
ARQT
$2.96B
$1.25M 0.29%
47,698
+18,606
+64% +$433K
AUPH icon
172
Aurinia Pharmaceuticals
AUPH
$2.15B
$1.25M 0.29%
73,507
+20,240
+38% +$323K
NVAX icon
173
Novavax
NVAX
$1.52B
$1.23M 0.29%
130,955
+2,450
+2% +$22K
HRMY icon
174
Harmony Biosciences
HRMY
$2.46B
$1.23M 0.29%
33,746
+12,906
+62% +$407K
NBIX icon
175
Neurocrine Biosciences
NBIX
$15.2B
$1.23M 0.29%
7,279
+1,755
+32% +$260K
5 6
7
8 9

Similar funds

MSG
Main Street Group Glen Allen, Virginia $429M AUM 34.03% 1-Year Est. Return
NL
Navalign LLC Encino, California $429M AUM 18.12% 1-Year Est. Return
PG
Prostatis Group Hanover, Maryland $429M AUM 26.55% 1-Year Est. Return
LFGO
Legacy Financial Group (Oklahoma) Tulsa, Oklahoma $429M AUM 21.51% 1-Year Est. Return
SFWC
Strategic Family Wealth Counselors Fairfield, New Jersey $430M AUM 17.41% 1-Year Est. Return
RS
Rakuten Securities Tokyo, Japan $430M AUM 189.97% 1-Year Est. Return
T
TrueFG Cedar Park, Texas $428M AUM 21.6% 1-Year Est. Return
WBC
West Branch Capital Amherst, Massachusetts $430M AUM 41.9% 1-Year Est. Return

Virtus Investment Advisers's Q2 2026 Portfolio in Review

As of Q2 2026, Virtus Investment Advisers held 517 positions worth $429M, up 18% from $363M the previous quarter. Its ten largest holdings account for 7.6% of the portfolio.

Virtus Investment Advisers deployed $19.4M of net new capital in Q2 2026, opening 67 new positions and adding to 228 existing holdings. Its largest new stake was Devon Energy: 74,863 shares worth $3.09M.

By sector, the portfolio is most concentrated in Healthcare at 39% of assets, up from 32% a quarter earlier, followed by Technology and Financials.

On the sell side, the largest reduction was ImmunityBio, an estimated $1.47M trimmed.

  • Virtus Investment Advisers's largest Q2 2026 buy was Devon Energy: 74,863 shares worth $3.09M.
  • Virtus Investment Advisers added most to Omeros in Q2 2026, an estimated $1.26M increase.
  • Virtus Investment Advisers's biggest Q2 2026 reduction was ImmunityBio, cutting an estimated $1.47M.
  • Virtus Investment Advisers fully exited Day One Biopharmaceuticals in Q2 2026, selling an estimated $2.17M.
  • Virtus Investment Advisers's ten largest holdings make up 7.6% of its $429M portfolio in Q2 2026.
  • Virtus Investment Advisers opened 67 new positions and closed 54 in Q2 2026.
  • Virtus Investment Advisers's portfolio value rose 18% quarter-over-quarter to $429M.

Based on Virtus Investment Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.